Fig. 4
Approach to the management of patients with relapsed CLL who meet the 2018 International Workshop for Chronic Lymphocytic Leukemia (iwCLL) criteria for therapy. BTKi Bruton tyrosine kinase inhibitors, IGHV immunoglobulin heavy chain gene, mAb monoclonal antibody.
